A British biotech spun out from SmithKline Beecham in the 1990s is on the brink of a breakthrough in the hunt for the “holy grail” of allergy research – a vaccine for peanut allergy sufferers.
AIM-listed Allergy Therapeutics, based in Worthing, is seeking permission with the US Food and Drug Administration regulator to begin human trials of its short-course jab next year following the publication of results from tests run in collaboration with London’s Imperial College.
Allergy Therapeutics plc (LON:AGY) is a market-leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.